Cumulus Neuroscience Presents NeuLogiq Data on Digital Endpoints for CNS Trials
Cumulus Neuroscience presented new data at the ISCTM Autumn Conference and ECNP Congress, highlighting the use of its NeuLogiq Platform for digital biomarkers in CNS clinical trials. The company showcased studies on major depressive disorder and dementia, showing improved sensitivity and efficiency in trial design.